AR075894A1 - Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos. - Google Patents
Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos.Info
- Publication number
- AR075894A1 AR075894A1 ARP100100883A ARP100100883A AR075894A1 AR 075894 A1 AR075894 A1 AR 075894A1 AR P100100883 A ARP100100883 A AR P100100883A AR P100100883 A ARP100100883 A AR P100100883A AR 075894 A1 AR075894 A1 AR 075894A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- branched
- linear
- group
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
También se refiere a procesos para su preparacion y a composiciones farmacéuticas que los contienen, para el tratamiento de trastornos neurologicos o isquemia cerebral, para los cuales la inhibicion de receptor de adenosina A2A dará como resultado la mejoría del estado de salud de un paciente. Reivindicacion 1: Un compuesto que tiene la formula general 1: R1 = es alquilo C1-6 lineal o ramificado; R2 es un grupo de la formula R9-(CHR8)p-(CR6R7)m-(CR4R5)n-; R4, R6 y R8 son, independientemente H, hidroxilo o =O, con el significado de carbonilo; R5, R7 y R9 son, independientemente, H o están ausentes; m, n y p son, independientemente un numero entero comprendido entre 0 y 2; m + n + p >=4; R3 es NH2, NHR10; R10 es alquilo C1-6 o hidroxialquilo C1-6, alcoxialquilo C1-3, amino(C1-6)alquilo, donde el grupo amino está sustituido, opcionalmente por uno o dos grupos alquilo C1-3, siendo los citados grupos alquilo lineales o ramificados; arilo C6-14 o arilo C6-14-alquilo C1-6, con el grupo arilo sustituido opcionalmente por uno o más sustituyentes, ya sea iguales o diferentes, seleccionados por el grupo constituido por halogeno, hidroxi, alcoxi C1-6 lineal o ramificado, saturado o insaturado, amino, mono- o di-sustituidos con alquilo C1-6 lineal o ramificado; sus formas opticamente activas, tales como enantiomeros, diastereomeros y sus formas de racemato y sales farmacéuticamente aceptables de los mismos; con la condicion de que R4, R6 y R8 no sean todos H al mismo tiempo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155690 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075894A1 true AR075894A1 (es) | 2011-05-04 |
Family
ID=40941572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100883A AR075894A1 (es) | 2009-03-20 | 2010-03-19 | Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9133197B2 (es) |
| EP (1) | EP2408775B1 (es) |
| JP (1) | JP5648044B2 (es) |
| AR (1) | AR075894A1 (es) |
| DK (1) | DK2408775T3 (es) |
| ES (1) | ES2542555T3 (es) |
| HR (1) | HRP20150766T1 (es) |
| HU (1) | HUE025704T2 (es) |
| PL (1) | PL2408775T3 (es) |
| PT (1) | PT2408775E (es) |
| SI (1) | SI2408775T1 (es) |
| SM (1) | SMT201500174B (es) |
| TW (1) | TWI473809B (es) |
| WO (1) | WO2010106145A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| MX2020003732A (es) * | 2017-09-28 | 2021-06-29 | Cstone Pharmaceuticals Suzhou Co Ltd | Derivado de anillo fusionado como inhibidor del receptor a2a. |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| NZ767596A (en) | 2018-03-14 | 2022-01-28 | Surface Oncology Inc | Antibodies that bind cd39 and uses thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗ｃｄ３９抗體組合物及方法 |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| US20210115127A1 (en) | 2019-09-25 | 2021-04-22 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
| AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1688599A (en) * | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| DK1221444T3 (da) * | 1999-07-02 | 2005-11-14 | Eisai Co Ltd | Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus |
| DK1272897T3 (da) * | 2000-02-10 | 2008-09-15 | Univ New York | Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever |
| ES2247356T3 (es) * | 2001-06-29 | 2006-03-01 | Cv Therapeutics, Inc. | Derivados de purina com antagonistas del receptor a2b de adenosina. |
| ITRM20010465A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| WO2003020723A1 (fr) * | 2001-08-30 | 2003-03-13 | Kyowa Hakko Kogyo Co., Ltd. | Derive de [1,2,4]triazolo[1,5-a]pyrimidine |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| JPWO2006129626A1 (ja) * | 2005-05-30 | 2009-01-08 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
-
2010
- 2010-03-18 PT PT107095267T patent/PT2408775E/pt unknown
- 2010-03-18 PL PL10709526T patent/PL2408775T3/pl unknown
- 2010-03-18 EP EP10709526.7A patent/EP2408775B1/en active Active
- 2010-03-18 WO PCT/EP2010/053554 patent/WO2010106145A1/en active Application Filing
- 2010-03-18 DK DK10709526.7T patent/DK2408775T3/en active
- 2010-03-18 JP JP2012500259A patent/JP5648044B2/ja active Active
- 2010-03-18 HU HUE10709526A patent/HUE025704T2/en unknown
- 2010-03-18 ES ES10709526.7T patent/ES2542555T3/es active Active
- 2010-03-18 US US13/257,750 patent/US9133197B2/en not_active Expired - Fee Related
- 2010-03-18 SI SI201030983T patent/SI2408775T1/sl unknown
- 2010-03-19 AR ARP100100883A patent/AR075894A1/es unknown
- 2010-03-19 TW TW99108187A patent/TWI473809B/zh not_active IP Right Cessation
-
2015
- 2015-07-13 HR HRP20150766TT patent/HRP20150766T1/hr unknown
- 2015-07-20 SM SM201500174T patent/SMT201500174B/xx unknown
- 2015-08-10 US US14/822,252 patent/US20160002244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2408775T3 (en) | 2015-07-27 |
| US9133197B2 (en) | 2015-09-15 |
| EP2408775A1 (en) | 2012-01-25 |
| US20160002244A1 (en) | 2016-01-07 |
| PL2408775T3 (pl) | 2015-10-30 |
| PT2408775E (pt) | 2015-08-05 |
| EP2408775B1 (en) | 2015-06-17 |
| US20120053191A1 (en) | 2012-03-01 |
| SMT201500174B (it) | 2015-10-30 |
| JP2012520854A (ja) | 2012-09-10 |
| TWI473809B (zh) | 2015-02-21 |
| HRP20150766T1 (hr) | 2015-08-14 |
| HUE025704T2 (en) | 2016-04-28 |
| ES2542555T3 (es) | 2015-08-06 |
| SI2408775T1 (sl) | 2015-08-31 |
| JP5648044B2 (ja) | 2015-01-07 |
| TW201100425A (en) | 2011-01-01 |
| WO2010106145A1 (en) | 2010-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075894A1 (es) | Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos. | |
| JOP20200154A1 (ar) | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 | |
| PH12018500763A1 (en) | New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| PH12017500252B1 (en) | New spiro[3h-indole-3,2`-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| GEP20207082B (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| CR20180452A (es) | Moduladores alostéricos de receptores de acetilcolina nicotícos | |
| ECSP12011857A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| CL2008003120A1 (es) | Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras. | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| MX2016013151A (es) | Nuevos derivados quinona de cannabidiol. | |
| ECSP15029822A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| BR112014026817A2 (pt) | derivados do pantotenato para o tratamento de transtornos neurológicos | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| MX2016010952A (es) | Nuevos derivados de cannabigerol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |